REGENXBIO

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regenxbio (RGNX) delivered earnings and revenue surprises of 125.84% and 284.87%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Regenxbio (RGNX) Surpasses Q3 Earnings and Revenue Estimates

Shares of Regenxbio (NASDAQ:RGNX) were flat after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 124.47% over the past year to $0.23, which beat the estimate of ($1.01).

Recap: Regenxbio Q3 Earnings

ROCKVILLE, Md., Oct. 28, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a...

REGENXBIO To Host Conference Call on November 4 to Discuss Third Quarter 2020 Financial Results and Recent Operational Highlights

China Biologic Products Holdings

Galapagos

Heron Therapeutics

Illumina

Ionis Pharma

Ligand Pharmaceuticals

It's a good time to separate the weak from the strong. The post 7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio appeared first on InvestorPlace.

7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio

uniQure

Sarepta Therapeutics

Voyager Therapeutics

Gene therapy - which aims to treat diseases by essentially inserting a gene into a patient’s cells rather than via drugs or surgery - was a hot trend in the biotech space, but investor interest in the sector appears to have died down considerably, on account of high R&D spending and delays.

Gene Therapy Stocks Continue To Underperform. Are They Worth A Look?

ROCKVILLE, Md., Sept. 30, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the expansion of the...

REGENXBIO Announces Continued Progress and Expansion of Clinical Development Program for RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II)

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of REGENXBIO Inc.

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating REGENXBIO Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

Advanced Micro Devices

Regenxbio: More Robust Data For Wet AMD

ROCKVILLE, Md., Sept. 9, 2020 /PRNewswire/ -- REGENXBIO Inc.

REGENXBIO Announces Dosing of First Patient in Phase II AAVIATE™ Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

ROCKVILLE, Md., Aug. 25, 2020 /PRNewswire/ -- REGENXBIO Inc.

REGENXBIO Announces FDA Clearance of IND for Phase II Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

REGENXBIO's (RGNX) CEO Ken Mills on Q2 2020 Results - Earnings Call Transcript

Regenxbio (RGNX) delivered earnings and revenue surprises of -2.25% and -14.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates

ROCKVILLE, Md., Aug. 6, 2020 /PRNewswire/ -- REGENXBIO Inc.

REGENXBIO Reports Second Quarter 2020 Financial Results and Operational Highlights

ROCKVILLE, Md., Aug. 4, 2020 /PRNewswire/ -- Company on track to initiate RGX-314 subretinal delivery pivotal program by the end of 2020 RGX-314 was generally well-tolerated in 42 patients at all dose levels in Phase I/IIa trial Positive interim update from Cohorts 4 and 5 at one year.

REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD

ROCKVILLE, Md., July 30, 2020 /PRNewswire/ -- REGENXBIO Inc.

REGENXBIO To Host Conference Call on August 6 to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights

Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Regenxbio (RGNX) to Report a Decline in Earnings: What to Look Out for

ROCKVILLE, Md., July 8, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it has completed...

REGENXBIO Provides Update on Progress of Clinical Programs for Rare Genetic Neurodegenerative Diseases

ROCKVILLE, Md., June 10, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced it will present at the...

REGENXBIO to Present at the Raymond James Human Health Innovation Conference

Becton, Dickinson and Co.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Boston Scientific

Omega Healthcare Investors

With the COVID-19 pandemic being the biggest health care story in years, it is no surprise that investors and traders have been closely watching and have been doing analysis on the top companies in the S&P health care sector, which returned a solid 3.1% in May.

Raymond James Makes Huge June Changes to Top Picks Health Care List

Adverum Biotechnologies

The Wet AMD Gene Therapy Race - Adverum Biotechnologies Vs. Regenxbio

Companies that have been able to deliver compelling results have been acquired by big pharma companies (for instance, Spark Therapeutics was acquired by Roche), while others have underperformed, due to large R&D investments and delays in launching revenue-generating products.

Gene Therapy Stocks Have Fallen Out Of Favor. Time To Buy?

REGENXBIO, Inc. (RGNX) CEO Kenneth Mills on Q1 2020 Results - Earnings Call Transcript

Regenxbio (RGNX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Regenxbio Is A Leader In Gene Therapies - A Case Where The Platform Is Worth More Than The Pipeline

Regenxbio: A Growth Stock For The Coronavirus Bear Market

News for REGENXBIO Stock (RGNX)